Stay updated with breaking news from Amgen Maritide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly , increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s.
Over 80 experimental obesity drugs have reached the human testing stage
As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading...
Eli Lilly's biggest growth drivers today are its weight loss drugs.
Goldman Sachs said Amgen's experimental GLP-1 drug could have peak sales of $5 billion, or 5% of the estimated $100 billion weight loss drug market.